At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Morgan Roupret, MD, of Hopital Pitié-Salpétrière, and Nadine Houede, MD, of Montpellier University, dissect their research on the safety and efficacy of neoadjuvant immunotherapy with durvalumab in combination with neoadjuvant gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma. ...
Upper Tract Urothelial Carcinoma
Advertisement
Latest News
Dr. Murray and Laura Bauer share their experiences treating patients with UTUC using mitomycin gel.
Patients who achieved a complete response after six doses of UGN-101 were followed up for 12 months after initial CR.
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
Drs. Michael Whalen and Vincent Xu discuss potential alternative treatments for patients who are ineligible for chemotherapy.
Drs. Michael Whalen and Vincent Xu discuss their recent analysis of neoadjuvant chemotherapy utilization for UTUC.
Drs. Sundaram and Murray highlight the results of a study on robotic nephroureterectomy and bladder cuff excision for UTUC.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
NLR can be a prognostic predictor of clinicopathology in UTUC, aiding risk stratification and management.
A meta-analysis sought to determine the surgical and oncological outcomes of LNU and ONU in patients with UTUC.
Advertisement
Roundtable Discussions
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
Urothelial Cancer Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.